Cervarix – Page 5 – Oral Cancer News

HPV Vaccine- Should it be Available for Boys?

Source: Dr.Bicuspid.com July 14, 2011 -- With the alarming rise in the rate of oropharyngeal cancer among men being linked to the human papillomavirus (HPV), the U.S. Centers for Disease Control and Prevention (CDC) is considering whether to also recommend the HPV vaccine for boys. Two vaccines (Cervarix and Gardasil) are currently available to protect females against the HPV types that cause most cervical cancers. The CDC currently recommends both for 11- and 12-year-old girls and for females 13 through 26 years old who did not get the three recommended doses when they were younger. The number of HPV-related oral cancers cases among men in the U.S. is increasing so quickly they could surpass the number of cases of cervical cancers in women by 2020, according to research presented last month at the American Society of Clinical Oncology annual meeting in Chicago. Between 1984 and 1989, only 16% of oropharyngeal cancers were linked to HPV. But by 2000-2004, HPV was related to 75% of oropharyngeal cancers, according to the National Cancer Institute (NCI). In 2010, the institute estimated that there were 12,660 cases of oropharyngeal cancer, resulting in 2,410 deaths. About half of those cases were among males and at least 75% were caused by HPV, according to NCI researchers. Several studies and oral cancer specialists have attributed the sharp rise in HPV-positive oropharyngeal cancers to an increasing prevalence of oral sex among young people. For the past few years, the CDC's Advisory Committee on Immunization Practices (ACIP) has been [...]

Oral Cancer Foundation News Team - A2011-07-14T09:53:49-07:00July, 2011|Oral Cancer News|

Men likely at greater risk for developing HPV-positive cancers

Source: curetoday.com Author: Jon Garinn A new analysis from the National Cancer Institute suggests that the number of HPV-positive oral cancers among men could rise significantly in the next decade, possibly surpassing HPV-positive cervical cancers among women. The genital human papillomavirus (HPV) is the most common sexually transmitted infection in the U.S., according to the Centers for Disease Control and Prevention. About 20 million Americans are currently infected and about 6 million are infected each year. Using population-based cancer registry data, the researchers found that between 1988 and 2004, oropharyngeal cancers related to HPV increased by 225 percent, with men accounting for the majority of cases. Relying on U.S. Census projections and age-period-cohort models, they projected a 27 percent rise in cases by 2020. More than 40 types of HPV are spread during genital, oral or anal sex with an infected partner—some are low-risk (wart-causing) while others are high-risk (cancer-causing). In most cases, the body’s own immune system gets rid of HPV within about two years of infection. But if the body cannot clear the infection, it can develop into several cancers, including oropharyngeal and cervical, which is the second leading cause of cancer deaths in women worldwide. Gardasil, the only approved vaccine for young men and women, is effective against two types of cancer-causing HPV and two types of wart-causing HPV. Cervarix is an HPV vaccine approved only for women.

Oral Cancer Foundation News Team - A2011-07-11T22:06:00-07:00July, 2011|Oral Cancer News|

We owe it to our sons to protect them against human papilloma virus – the new oral cancer peril

Source: www.dailymail.co.uk Author: Professor Lawrence Young The seemingly unstoppable rise of throat and mouth cancers over the past two decades has left experts baffled and deeply concerned. These are truly horrible diseases. More than 15,000 new patients are diagnosed each year in Britain alone and almost 8,000 die from the most common type, cancer of the oesophagus. Two-thirds of sufferers are men. And those that survive are often left horrifically disfigured by aggressive radiotherapy and surgery. Most worryingly, numbers of new cases have doubled since 1989. We used to think most oral and throat cancers - which also include laryngeal (voice box), tracheal (windpipe) and oropharyngeal (soft-palate) tumours - were due to a lifetime of smoking and heavy alcohol consumption, and only really occurred in old age. But as health messages hit home, numbers of smokers and drinkers dropped, fewer older men and women developed these cancers and a new group of patients - middle-class, middle-aged men who drank moderately and had never smoked - emerged. This was a surprise. Small studies, in which tumours were analysed, indicated a new culprit: the human papilloma virus (HPV), the same virus that we knew was the cause of cervical cancer in women. For years there have been whisperings among oncologists that this could become one of the most significant cancer challenges of the 21st Century. And six weeks ago, evidence published by two American universities showed that these fears were becoming a reality. Researchers found that about half of the [...]

Oral Cancer Foundation News Team - A2011-04-03T09:40:53-07:00April, 2011|Oral Cancer News|

Virus passed during oral sex tops tobacco as throat cancer cause

Source: www.npr.org Author: Peggy Girshman If you're keeping score, here's even more evidence that HPV causes oral, head and neck cancers and that vaccines may be able to prevent it. Researchers studying the human papilloma virus say that in the United States HPV causes 64 percent of oropharynxl cancers. In the rest of the world, tobacco remains the leading cause of oral cancer, Dr. Maura Gillison of Ohio State University told a meeting of the American Association for the Advancement of Science this past weekend. And the more oral sex someone has had — and the more partners they've had — the greater their risk of getting these cancers, which grow in the middle part of the throat. "An individual who has six or more lifetime partners — on whom they've performed oral sex – has an eightfold increase in risk compared to someone who has never performed oral sex," she said. The recent rise in oropharnx cancer is predominantly among young, white men, she noted, though she says no one has figured out why yet. About 37,000 people in the United States were diagnosed with oral cancer in 2010, according to the Oral Cancer Foundation. People with HPV-related throat cancer are more likely to survive their cancer than those who were heavy smokers or drinkers, the other big risk factors. The message may be more critical for teens according to Bonnie Halpern-Felsher, professor of pediatrics at the University of California, San Francisco. She has studied 600 adolescents over 10 [...]

Oral Cancer Foundation News Team - A2011-02-24T10:24:37-07:00February, 2011|Oral Cancer News|

How protein made by HPV thwarts protective human protein, causing malignancy

Source: American Society for Biochemistry and Molecular Biology BETHESDA, MD., Jan. 11, 2011 – An international team of researchers is reporting that it has uncovered new information about human papilloma virus that one day may aid in the development of drugs to eliminate the cervical-cancer-causing infection. Led by researcher Per Jemth of Uppsala University in Sweden, the collaborators from four institutions detail in the Journal of Biological Chemistry how an offensive protein generated by the sexually transmitted virus handicaps a defensive protein made by the human body. Co-author Neil Ferguson, a biophysicist at University College Dublin, says: "It has proved difficult to stem the proliferation of many viruses using conventional drug discovery. Inhibitors of protein-protein interactions, as in HPV's case, are potentially potent ways to perturb viral infections." There are almost 200 strains of HPV, dozens of which are transmitted through genital contact, and about half of sexually active people have had one or more infections. The immune system eliminates the virus within two years in about 90 percent of cases, according to the Centers for Disease Control and Prevention in Atlanta, but it lingers for many years in a minority of cases. Some strains result in no visible symptoms, others cause genital warts and still others cause cancer. "Infection by high-risk human papilloma viruses is causing as many as half a million cases of cervical cancer and more than 200,000 deaths among women per year, making it one of the most common forms of cancer," Jemth emphasized. For the [...]

Oral Cancer Foundation News Team - A2011-01-17T21:36:34-07:00January, 2011|Oral Cancer News|

A cancer vaccine is born

Source: www.rochester.edu Author: Corydon Ireland Room 3-5135 at the Medical Center looks like a hundred other cubbyholes of basic science. A gray metal door decorated with the obligatory cartoon leads into a space the size of a motel room. White lab coats drape on wire hangers. Plain shelves, a desk, and a computer surround a breast-high bench arrayed with instrumentation. The paint scheme: early dorm room. “The posters are to cover the holes in the walls,” jokes William Bonnez, an associate professor of medicine and a veteran researcher who says not much has changed inside the room in a quarter century. But this is no ordinary workspace, and some day it may merit a plaque. Here, starting more than two decades ago, Bonnez and University colleagues Richard Reichman, a professor of medicine, and Robert Rose ’94M (PhD), an associate professor of medicine, developed the key technology behind two vaccines that may eliminate cervical cancer, a disease that each year kills 250,000 women internationally, including 4,500 Americans. One vaccine using the Rochester technology is Gardasil, developed by pharmaceutical giant Merck, that’s expected to be on the market some time this year. Another candidate is Cervarix, developed by GlaxoSmithKline, that could be ready by 2008. Gardasil “is a phenomenal breakthrough,” Gloria A. Bachmann told Newsday last fall when results of the final trial for the vaccine were released. She’s director of the Women’s Health Institute at the Robert Wood Johnson Medical School in New Jersey and was not involved with the Rochester [...]

Oral Cancer Foundation News Team - A2011-01-04T20:18:41-07:00January, 2011|Oral Cancer News|

HPV vaccination of young women may protect men through herd immunity

Source: www.medscape.com Author: Laurie Barclay, MD High coverage of quadrivalent human papillomavirus (HPV) vaccination in young Australian women resulted in a lower frequency of genital warts, which might protect heterosexual men through herd immunity, according to the results of an analysis of national sentinel surveillance data published online November 9 in Lancet Infectious Diseases. "The natural history of cervical and HPV-associated diseases is slow," Mark H. Einstein, MD, MS, associate professor of obstetrics and gynecology and women's health, and director of clinical research for women's health and gynecologic oncology at Albert Einstein College of Medicine and Albert Einstein Cancer Center, Montefiore Medical Center, in New York City, told Medscape Medical News when asked for independent comment. "This is the first registry-based study that has already shown the declines after vaccinating a large population of vaccine-eligible adolescents and young adults. This prospectively shows what all the models have been predicting all along." The annual incidence of genital warts has been increasing for decades and is currently about 1% in young, sexually active people. Up to 90% of cases of genital warts are caused by HPV types 6 and 11, which are 2 of the 4 types targeted by the quadrivalent HPV vaccine used in Australia (Gardasil; CSL Biotherapies). "While it will probably be as effective as the quadrivalent HPV vaccine at preventing anogenital and other cancers, the bivalent HPV vaccine (Cervarix, GSK) used in the UK national program provides no protection against genital warts," lead author Basil Donovan, MD, head of [...]

Oral Cancer Foundation News Team - A2010-11-21T12:53:34-07:00November, 2010|Oral Cancer News|

GlaxoSmithKline Drops the Price of Cervarix

Source: PharmaLive MISSISSAUGA, ON, Oct. 25 /CNW/ - Today, GlaxoSmithKline Inc. (Canada), announced its plan to reduce the cost of CERVARIX™ by 30%. The cost reduction is in response to recent research that demonstrates the relatively high price of cervical cancer vaccines, coupled with a low understanding of their protective benefits topped the list of reasons why the majority of young Canadian women have yet to be immunized. Last week, research supported by The Society of Gynecologic Oncology of Canada (GOC), The Society of Obstetricians and Gynaecologists of Canada (SOGC), the Federation of Medical Women of Canada (FMWC), and the Society of Canadian Colposcopists (SCC) revealed that 9 out of 10 Canadian women aged 18 to 25 have not been vaccinated against cervical cancer. Half of young women polled (who do not have a private drug plan) cited cost as a barrier to obtaining the vaccine and 61% of mothers of young women agreed that cost was a deterring factor. In fact, 50% of non-vaccinated women aged 18 to 25 without vaccine coverage through their drug plan and 61% of mothers with daughters in this age group cited cost as a deciding factor. This is particularly relevant as 60% of Canadians do not have vaccine coverage through private insurance.1 As a patient-focused company, GlaxoSmithKline Inc. was concerned to learn that the cost of cervical cancer vaccines is deterring women from protecting themselves from a largely preventable disease that kills one Canadian woman every day.2 Effective today, October 25, 2010, the [...]

Charlotte Parker2010-10-26T13:57:51-07:00October, 2010|Oral Cancer News|

GSK European Commission amends licence for Cervarix

By: GlaxoSmithKline Source: PharmPro GlaxoSmithKline (GSK) confirmed today that the European Commission has granted Marketing Authorisation to amend the licence for its cervical cancer vaccine, Cervarix®. The approval from the European Commission is important as it recognises the extent of cervical cancer protection demonstrated by Cervarix®, which was not highlighted by the previous indication. The licence amendment is supported by data from the largest efficacy trial of a cervical cancer vaccine conducted to date, the PATRICIA study, and acknowledges that Cervarix® has shown efficacy beyond HPV 16 and 18, the two virus types contained in the vaccine. The summary of product characteristics (SPC) for Cervarix® will be updated to include the prevention of precancerous lesions and cervical cancer causally related to certain strains of the human papillomavirus (HPV) and will reflect data showing efficacy against the two vaccine types contained in the vaccine (HPV 16 and 18) and the three next most common cancer-causing virus types (HPV 31, 33 and 45).* Together these five HPV types (16, 18, 31, 33 and 45) account for 80 percent of all cervical cancers. * Vaccine efficacy is different for each of the HPV types 16, 18, 31, 33 and 45, and varies in different cohorts and endpoints. GlaxoSmithKline Biologicals (GSK Biologicals), GlaxoSmithKline’s vaccines business, is one of the world’s leading vaccine companies and a leader in innovation. The company is active in vaccine research, development and production with over 30 vaccines approved for marketing and 20 more in development - both in the prophylactic and therapeutic fields [...]

Charlotte Parker2010-09-17T09:07:55-07:00September, 2010|Oral Cancer News|

European Commission amends licence for Cervarix

Source: www.pharmpro.com Author: press release GlaxoSmithKline (GSK) confirmed today that the European Commission has granted Marketing Authorisation to amend the licence for its cervical cancer vaccine, Cervarix®. The approval from the European Commission is important as it recognises the extent of cervical cancer protection demonstrated by Cervarix®, which was not highlighted by the previous indication. The licence amendment is supported by data from the largest efficacy trial of a cervical cancer vaccine conducted to date, the PATRICIA study, and acknowledges that Cervarix® has shown efficacy beyond HPV 16 and 18, the two virus types contained in the vaccine. The summary of product characteristics (SPC) for Cervarix® will be updated to include the prevention of precancerous lesions and cervical cancer causally related to certain strains of the human papillomavirus (HPV) and will reflect data showing efficacy against the two vaccine types contained in the vaccine (HPV 16 and 18) and the three next most common cancer-causing virus types (HPV 31, 33 and 45).* Together these five HPV types (16, 18, 31, 33 and 45) account for 80 percent of all cervical cancers. Note: 1. Vaccine efficacy is different for each of the HPV types 16, 18, 31, 33 and 45, and varies in different cohorts and endpoints.

Oral Cancer Foundation News Team - A2010-08-25T05:27:36-07:00August, 2010|Oral Cancer News|